✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Pracinostat is an investigational drug.
There have been 10 clinical trials for Pracinostat. The most recent clinical trial was a Phase 2 trial, which was initiated on June 23rd 2017.
The most common disease conditions in clinical trials are Leukemia, Myeloid, Leukemia, and Syndrome. The leading clinical trial sponsors are Helsinn Healthcare SA, MEI Pharma, Inc., and M.D. Anderson Cancer Center.
There are seventy-eight US patents protecting this investigational drug and nine hundred and twelve international patents.
Recent Clinical Trials for Pracinostat
|Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid Leukemia||Medical College of Wisconsin||Phase 1|
|A Study In Healthy Male Volunteers Designed To Investigate How A Radiolabelled Medicine Is Broken Down And Removed From The Body||Quotient Sciences||Phase 1|
|A Study In Healthy Male Volunteers Designed To Investigate How A Radiolabelled Medicine Is Broken Down And Removed From The Body||Helsinn Healthcare SA||Phase 1|
Top disease conditions for Pracinostat
Top clinical trial sponsors for Pracinostat
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Pracinostat||See Plans and Pricing||Histone deacetylase inhibitors and methods for use thereof||REACTION BIOLOGY CORP. (Malvern, PA)||See Plans and Pricing|
|Pracinostat||See Plans and Pricing||Anti-CS1 antibodies and antibody drug conjugates||AbbVie Biotherapeutics Inc. (Redwood City, CA)||See Plans and Pricing|
|Pracinostat||See Plans and Pricing||Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: III||Frequency Therapeutics, Inc. (Woburn, MA)||See Plans and Pricing|
|Pracinostat||See Plans and Pricing||Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids||Cantex Pharmaceuticals, Inc. (Weston, FL)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Pracinostat||World Intellectual Property Organization (WIPO)||WO2017030892||2035-08-14||See Plans and Pricing|
|Pracinostat||Australia||AU2015339012||2034-10-31||See Plans and Pricing|
|Pracinostat||Brazil||BR112017008945||2034-10-31||See Plans and Pricing|
|Pracinostat||Canada||CA2966005||2034-10-31||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|